Based on recommendations from HF guidelines [5], patients with HF and reduced ejection fraction (HFrEF) should receive a renin–angiotensin system (RAS) inhibitor, beta-blocker and mineralocorticoid receptor antagonist (MRA) therapy. Here, REN is linked to hydrops fetalis.